onlyuse ersonal1

CYCLOPHARM

Investor Update

Bell Potter HealthCare Conference

James McBrayer, CEO & Managing Director

10 November 2021

onlySAFE

useHARBOUR STATEMENT

ersonal2

Certain views expressed here contain information derived from publicly available sources that have not been independently verified.

The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm Limited and as to the markets for the company's products. Such statements, estimates and projections reflect various assumptions made by the directors concerning anticipated results, which assumptions may or may not prove to be correct. Cyclopharm Limited has not sought independent verification of information in this presentation.

While the directors believe they have reasonable grounds for each of the statements, estimates and projections and all care has been taken in the preparation, no representation or warranty, express or implied, is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of statements, estimates and projections contained in this presentation. Such statements, estimates and projections are by their nature subject to significant uncertainties, contingencies and assumptions.

To the maximum extent permitted by law, none of the Cyclopharm Limited, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of information contained in this presentation.

All references to dollars unless otherwise specified are to Australian dollars.

Investor Update

COMPANY OVERVIEW

Cyclopharm Limited (CYC) is a Leading Diagnostic Lung Imaging Company

only1

2

use3

ersonal4

5

3

Lead nuclear medicine product Technegas® is currently available in 60 countries with significant opportunity to expand into the USA with sales targeted for mid 2022 following completion of USFDA Complete Response Letter submission

The gold standard & world leader in functional lung ventilation imaging technology - supported by 4.4 million patient studies and 100's of peer reviewed published studies with COVID-19applications for use

Recurring consumables and capital equipment revenue streams

A profitable and growing company with a history of dividend payments

Opportunity to broaden Technegas® applications Beyond pulmonary embolism diagnosis into large addressable markets such as COPD and Asthma

PRESENTATION HIGHLIGHTS

Recovery Post COVID and Progress to USA Approval

only1

2

use3

ersonal4

5

4

Recovery in FY 2021 from initial COVID-19 impact in primary country markets

Continued profitability and positive cash flow from sales of Technegas across 60 countries with additional revenues growing from third party distribution

Progress towards USA market entry -Type B meeting granted & targeting mid-2022 for USFDA approval

Ongoing soon to be published studies "Beyond PE" to significantly expand clinical applications to include asthma, COPD, Long COVID…..

Strong Balance Sheet to fully fund growth strategy - $31.7m net cash as at 30 June 2021

Investor Update 10/11/2021

TECHNEGAS ®

World's Best Functional Lung Ventilation Imaging Agent

onlyuse ersonal5

Patient inhales extremely small carbon particles labeled with 99mTechnetium1

The small size and hydrophobic properties demonstrates gas like-behavior and alveoli deposition into the lungs2-3

Clinicians can visualise functional ventilation using Technegas®

Investor Update

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Cyclopharm Limited published this content on 09 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 November 2021 05:52:03 UTC.